Ó³»­´«Ã½

Winston Yan leads the Center for Genetic Surgery (CGS) at the Ó³»­´«Ã½. He is a physician-scientist and genome engineer motivated by using genetic medicines to treat patients, particularly those with rare genetic disease for which no treatments exist. CGS, established by the Ó³»­´«Ã½ in collaboration with partners across hospitals, industry, research institutes, and patient advocacy groups, aims to advance genetic therapies for patient populations that are too rare or too challenging for traditional commercial development. 

Yan is a co-founder and, most recently, was director of clinical development at Arbor Biotechnologies, with firsthand experience taking Arbor's lead therapeutic program from discovery to dosing patients. Over nearly nine years at Arbor, he helped lead Arbor’s early strategy and fundraising, build close-knit teams and organizational culture, led scientific platform development and translational strategy, authored clinical and regulatory documents towards IND and CTA acceptance, and served as clinical lead of a global first-in-human CRISPR gene editing trial. He is also the founding president of the N=1 Collaborative, an international consortium dedicated to enabling the development of individualized genetic medicines. 

Yan completed his undergraduate degree in physics magna cum laude at Harvard College, his M.D. from Harvard Medical School through the Health Sciences & Technology (HST) program, and his Ph.D. from Harvard University, working at the Ó³»­´«Ã½ with Feng Zhang on early CRISPR genome editing technology development.